Baricitinib is an oral JAK 1/2 inhibitor that ... The therapy also rapidly reduced interferon activity, a key signaling molecule in the disease, as well as reduced the specific, pathogenic T ...

42.4% of adolescents with severe alopecia areata who received baricitinib had 80% or more scalp hair coverage after 36 weeks. An expert said it is the largest trial to date studying treatment in ...

In an interview with Brittany Craiglow, MD, FAAD, dermatologist at Dermatology Physicians of Connecticut in Fairfield, she advocates for combination therapies using baricitinib to treat pediatric ...

Brittany Craiglow, MD, FAAD, analyzed the promising use of baricitinib for severe pediatric alopecia areata. She highlighted late-breaking data from the BRAVE-AA-PEDS study (NCT05723198 ...